Overexpression of a Heterologous Thymidine Kinase Delays Apoptosis Induced by Factor Deprivation and Inhibitors of Deoxynucleotide Metabolism*

(Received for publication, July 17, 1996, and in revised form, January 31, 1997)

F. Javier Oliver Dagger , Mary K. L. Collins § and Abelardo López-Rivas Dagger

From the Dagger  Instituto de Parasitología y Biomedicina, Consejo Superior de Investigaciones Científicas, 18001 Granada, Spain and the § Institute of Cancer Research, Chester Beatty Laboratories, London SW3 6JB, United Kingdom

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

Perturbing deoxyribonucleoside triphosphate (dNTP) metabolism with inhibitors of the de novo synthesis of dNTP causes apoptosis in the interleukin-3 (IL-3)-dependent pre-B cell line BAF3. Under these conditions apoptosis is prevented when deoxyribonucleosides for dNTP synthesis are supplied in the culture medium. On the other hand, removal of IL-3 from cultures of BAF3 cells resulted in down-regulation of thymidine kinase activity, rapid imbalance in dNTP levels, and apoptosis. In this study we show that overexpression of a heterologous thymidine kinase, herpes simplex virus thymidine kinase (TK), in BAF3 cells protects these cells from apoptosis induced by either inhibitors of dNTP synthesis or IL-3 deprivation. This protection against apoptosis is abrogated by 9-(4-hydroxybutyl)-N2-phenylguanine, a specific inhibitor of herpes simplex virus-1 TK. These results suggest that deoxyribonucleoside kinases, particularly TK, may be important in the regulation of apoptosis in hemopoietic cells.


INTRODUCTION

Cell population dynamics depend upon changes in the balance between cell proliferation and death. Transformed cells may be those that either proliferate in the absence of growth factors or fail to undergo apoptosis upon factor removal (1). Tumor cells are susceptible to apoptosis, and certain therapeutic strategies for cancer have been developed to induce apoptosis. Indeed, a number of antineoplastic drugs and treatments exert their cytotoxic effect by inducing apoptosis (2). Furthermore, the drug and radiation resistance of many tumors can be ascribed to the failure of cancer cells to enter apoptosis due, for example, to mutations in p53 or deregulation of the expression of proteins of the bcl-2 family (1, 3).

The maintenance of balanced dNTP1 pools is critical for DNA replication and repair; under normal culture conditions, it is mainly achieved by regulation of the activity of enzymes of the de novo pathway of synthesis of dNTPs (4). Whereas moderate perturbation of dNTP pools affects genetic stability of cells (5), with the appearance of frequent mutations (6) and strand breaks (7), severe imbalance of dNTP pools causes cell death (8). Several antineoplastic agents that inhibit DNA precursor synthesis have been reported to kill lymphoid cells by induction of apoptosis (3), and inherited deficiencies in enzymes such as adenosine deaminase and purine nucleoside phosphorylase, which produce imbalanced accumulation of dNTPs, result in lymphoid cell death (9). Previous results from our laboratory have shown that inhibition of thymidylate synthase (an enzyme of the de novo synthesis of dNTP) with 5-fluoro-2'-deoxyuridine, which perturbs deoxyribonucleotide metabolism, drives the IL-3-dependent cell line BAF3 to enter apoptosis even in the presence of IL-3 (10). Furthermore, removal of IL-3 from BAF3 cell cultures leads to an early imbalance in dNTP pools during apoptosis (11).

In addition to the de novo pathway for dNTP synthesis, mammalian cells, in particular those of the immune system, contain kinase activities for deoxyribonucleosides (4). These salvage enzymes function in the reutilization of degradation products from nucleic acids or precursors from the extracellular medium. Thymidine kinase is perhaps the best characterized of these enzymes; its substrates are thymidine and deoxyuridine, and it is inhibited by dTTP (4). It has been used as a malignancy marker for a variety of tumors (12, 13), and tumor cells deficient in this enzyme show a lower oncogenic potential than the wild-type cells from which they derive (14). Moreover, a recent report has also demonstrated that TK is a major radioresponse determinant in rat glioma cells (15).

It has been suggested that this reutilization pathway, acting in a concerted manner with other salvage enzymes and the de novo pathway, could also regulate intracellular levels of dNTPs (4) and protect cells from apoptosis (16-18). Here, we show that the potentiation of this salvage pathway either by the supply of dNTP precursors or by overexpression of a heterologous TK (HSV-1 TK) delays programmed cell death induced by IL-3 deprivation and drugs that inhibit dNTP metabolism in BAF3 cells.


EXPERIMENTAL PROCEDURES

Materials

RPMI 1640 medium and fetal bovine serum were obtained from Life Technologies, Inc. Methotrexate was from Cyanamid Iberica, Division Lederle. Deoxy[8-3H]ATP (24 Ci/mmol), deoxy[8-3H]GTP (16.9 Ci/mmol), deoxy[5-3H]CTP (18 Ci/mmol), and [methyl-3H]thymidine (49 Ci/mmol) were from Amersham. [methyl-3H]TTP (40 Ci/mmol) was purchased from ICN Biochemicals. Synthetic DNA templates, 5-fluoro-2'-deoxyuridine, hydroxyurea, and other reagents of the purest grade available were obtained from Sigma and Boehringer Mannheim. The HSV-1 TK inhibitor 9-(4-hydroxybutyl)-N2-phenylguanine (HBPG) was kindly provided by Dr. George E. Wright (University of Massachusetts Medical School, Worcester, MA).

Cell Cultures and Transfection Experiments

Murine IL-3-dependent BAF3 cells (19) were maintained in RPMI medium containing 10% fetal bovine serum, 1 mM glutamine, and 10% conditioned medium from the IL-3-producing cell line Wehi-3B. For transient expression experiments, BAF3 cells were transfected with HSV1-TK cDNA cloned into MFG-S plasmid (Somatix) or with a control cDNA (the neomycin-resistance gene, neo) by electroporation of 10-20 µg of DNA at 350 V or alternatively by lipofection with 5 µg of Lipofectin (Life Technologies, Inc.) and 2.5 µg of DNA. Cells were cultured in the presence of IL-3 for 24-48 h, and thymidine kinase activity was measured. For stable expression of HSV thymidine kinase activity, cells were cotransfected by electroporation with the previous TK cDNA and a plasmid conferring resistance to puromycin, pBabe Puro (20). Puromycin was added at 4 µg/ml to the cultures to select cells expressing resistance to this marker.

Analysis of DNA fragmentation and cell cycle were performed according to published procedures (21).

Deoxyribonucleoside Triphosphate Pool Assay

Preparation of cell extracts was essentially as described (22). dNTPs were determined by the DNA polymerase assay (23) using a synthetic DNA template and the Klenow fragment of DNA polymerase. The intracellular concentrations of dNTP were estimated from calibration curves obtained using pure standards.

Thymidine Kinase Activity

Cells were pelleted and washed twice with ice-cold PBS. The pellet was then resuspended in 20 mM Tris-HCl, pH 7.0, 2 mM MgCl2, 20 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride, subjected to Dounce homogenization, and sonicated to completely disrupt the cells. The extract was cleared of cellular debris by centrifugation, and the remaining supernatant containing a minimum of 2 mg of protein/ml was assayed for TK activity essentially as described (24).

Statistical Analysis

The statistical significance of the data was determined after applying Student's t test.


RESULTS AND DISCUSSION

Deoxyribonucleosides Prevent the Induction of Apoptosis by Inhibitors of dNTP Synthesis in Hemopoietic BAF3 Cells

Dihydrofolate reductase and ribonucleotide reductase catalyze key steps in the de novo production of dNTPs. Inhibitors of these enzymes, such as methotrexate (MTX) and hydroxyurea (HU), are commonly used in antineoplastic treatment, and they also induce apoptosis in hemopoietic BAF3 cells even in the presence of IL-3 (10). After 8 h of treatment with either drug, loss of cell viability, as assessed by cell membrane integrity, was not observed (Fig. 1A); however, at this time DNA was digested into oligonucleosome-sized fragments (Fig. 1B). Cell death could be clearly observed after 15 h of treatment with either inhibitor. Addition of deoxyribonucleosides to the medium facilitates dNTP synthesis; these precursors are transported by a nonspecific permease across the cell membrane and modified by the action of deoxyribonucleosides kinases to generate dNTP pools (4), thus bypassing the de novo synthesis pathway. The presence of 50 µM thymidine in the culture medium completely prevented the appearance of the sub-G1 peak of apoptotic cells in cultures of BAF3 cells treated with MTX for 15 h (Fig. 1C) and inhibited DNA fragmentation and cell death (data not shown). Inhibition of HU-induced apoptosis was achieved by incubating the cells with 1 µM deoxyadenosine and 100 µM deoxyguanosine (Fig. 1C). This precursor combination was used in the study of Lagergren and Reichard (25), in which it reversed the inhibition of DNA synthesis by HU. These data suggest that salvage enzymes involved in the phosphorylation of these precursors are probably important in the maintenance of dNTP balance and the inhibition of cell death (17, 18). A similar role of this salvage pathway has been demonstrated in erythroblasts from mice with experimental folate deficiency anemia, in which the addition of thymidine is sufficient to protect cells from apoptosis (16).


Fig. 1. Addition of deoxyribonucleosides to the culture medium can regulate apoptosis in BAF3 cells. BAF3 cells cultured in the presence of IL-3 were incubated with 5 µM MTX or 1 mM HU. At different times after drug addition, cell viability was determined (A). Results are the average of three separate experiments. DNA was isolated from cells treated for 0, 5, 8, and 15 h with 5 µM MTX or 1 mM HU and subjected to agarose gel electrophoresis (B). C, BAF3 cells growing in the presence of IL-3 were incubated with 5 µM methotrexate (MTX), 5 µM methotrexate + 50 µM thymidine (MTX + T), 50 µM hydroxyurea (HU), or 50 µM hydroxyurea + 100 µM deoxyguanosine/1 µM deoxyadenosine (HU + AG) or with no addition (control) and incubated for 15 h. Cells were fixed, treated with propidium iodide, and subjected to fluorescence-activated cell sorter analysis as described previously (18).
[View Larger Version of this Image (26K GIF file)]


Overexpression of HSV-1 Thymidine Kinase Suppresses Apoptosis Induced by IL-3 Removal and Inhibitors of dNTP Synthesis

To determine the role of TK activity in the regulation of apoptosis, we have examined the effect of overexpressing heterologous HSV-1 TK (26) on the entry of cells into apoptosis after IL-3 withdrawal or drug treatment. Initially, we transiently expressed HSV-1 TK in BAF3 cells and determined both the level of TK activity and apoptosis in bulk-transfected cells. Bulk-transfected cell populations were deprived of IL-3 for 24 h, and viability was measured at this time. The results from eight independent transfection experiments are shown in Fig. 2A; a correlation was found between the level of expression of TK activity and protection from cell death. Whereas cell viability decreased to 20% in control (vector-transfected) cells, transfection of HSV-1 TK resulted in up to 83% viable cells after IL-3 deprivation. These trypan blue-excluding cells in the HSV-1 TK-transfected cultures were viable because they were able to grow in response to IL-3, with a generation time similar to that of cells not subjected to IL-3 withdrawal (data not shown).


Fig. 2. Expression of heterologous HSV thymidine kinase in BAF3 cells delays apoptosis induced by IL-3 deprivation. A, BAF3 cells were transiently transfected with either HSV-1 thymidine kinase or neo-containing plasmids as described in "Experimental Procedures," and the level of TK activity in the presence of IL-3 was measured. Transfected cells were subjected to IL-3 deprivation, and the percentage of viable cells after 24 h of cytokine deprivation was represented against the level of TK activity. The results shown are derived from eight independent transfections. B, BAF3 cells stably overexpressing the HSV-1 TK gene (TK2) or the puromycin resistance gene (puro3) were subjected to IL-3 deprivation for up to 48 h. TK activity in the presence of IL-3 was as follows: puro3, 0.30 nmol/mg protein/h; TK2, 2.6 nmol/mg protein/h. Results are the average ± S.D. of three different experiments.
[View Larger Version of this Image (14K GIF file)]


We next determined whether stable HSV-1 TK expression could inhibit apoptosis. By transfecting BAF3 cells with the HSV-1 TK cDNA, several clones were generated that expressed high levels of TK activity. From these clones, clone TK2 was chosen because it did not release any soluble factor to the culture media to allow cell survival in the absence of IL-3, which would mask the effect of TK overexpression. Cell viability in a control clone expressing only resistance to puromycin (puro3) decreased to less than 30% after 24 h in the absence of IL-3, and there was a complete loss of cell viability after 48 h of cytokine deprivation (Fig. 2B). In contrast, viability of TK2 cells was maintained at values higher than 90 and 30% after 24 and 48 h of IL-3 withdrawal, respectively (Fig. 2B). Furthermore, the clone overexpressing HSV-1 TK was able to maintain TK activity after deprivation of IL-3, in contrast to what was observed in puro3 cells (data not shown) and parental BAF3 cells (11). We have also determined the effect of HSV-1 TK overexpression on the viability of cells treated with inhibitors of dNTP metabolism such as MTX and FdUrd, which rapidly deplete the cells of dTTP. Results in Fig. 3A and B show that cells overexpressing HSV-1 TK are more resistant to cell death induced by increasing doses of FdUrd or MTX.


Fig. 3. Effect of HSV-1 TK overexpression on cell viability after MTX or FdUrd treatment. Cells growing in the presence of IL-3 were treated with different concentrations of FdUrd (A) or MTX (B), and cell viability was determined after 15 h of incubation. Results represent the average ± S.D. of three different experiments.
[View Larger Version of this Image (12K GIF file)]


We also measured intracellular dNTP levels after MTX treatment or IL-3 withdrawal in control and HSV-1 TK-transfected cells. The dNTP pools in untreated cultures from both cell types were not significantly different (Fig. 4, legend), but the cell response to an antimetabolite drug or IL-3 deprivation was markedly different (Fig. 4). Control cells treated for 3 h with 5 µM MTX exhibited a 66% decrease in dTTP and dGTP levels, whereas dATP and dCTP remained unchanged. In IL-3 deprivation experiments, the levels of dATP, dGTP, and dTTP after 8 h in the absence of IL-3 decreased to about 40-50% of the initial levels, whereas the dCTP level was only slightly changed, as reported previously (11). Interestingly, in cells overexpressing HSV-1 TK, treatment with MTX had no effect on the intracellular dATP, dGTP, and dTTP levels and had little effect on the dCTP pool (67% of the level found in untreated cells). Furthermore, removal of IL-3 from these cells did not induce a decrease in the values of all four dNTPs, showing a general maintenance of dNTP levels as a result of TK overexpression. Although one would have expected only the dTTP level to be maintained in HSV TK-overexpressing cells, allosteric activation of ribonucleotide reductase by dTTP might be responsible for the elevated pool of dGTP, which in turn can stimulate the reduction of ADP to dADP (27).


Fig. 4. Effect of HSV-1 TK overexpression on dNTP pools after MTX treatment or IL-3 withdrawal. The levels of dNTP in control and HSV TK cells were determined in neutralized perchloric cell extracts before and after 3 h of incubation with MTX or 8 h in the absence of IL-3, as described in "Experimental Procedures." Data shown are the average ± S.D. of at least two independent experiments. The initial levels of the various dNTPs (in picomoles/106 cells) were as follows: control cells, dATP (7.1 ± 1.9), dCTP (65.0 ± 18), dGTP (9.0 ± 1.3), and dTTP (27 ± 3.4); TK2 cells, dATP (11.8 ± 1.9), dCTP (58 ± 9.2), dGTP (8.8 ± 0.4), and dTTP (22.0 ± 3.5).
[View Larger Version of this Image (44K GIF file)]


Earlier reports have shown that introduction of herpes virus DNA into TK-deficient cells was able per se to alter the sensitivity to beta -interferon, irrespective of the acquisition of TK activity (28, 29). To rule out this possibility in our experiments, we took advantage of a recently characterized specific inhibitor of HSV-1 TK (30). This compound, HBPG, did not inhibit cellular TK activity as assayed in vitro on cell extracts from control cells and had no effect on [3H]thymidine incorporation in growing cells (data not shown). Fig. 5A shows that HBPG did not affect the cell viability of control cells in either the presence or absence of IL-3. However, in clones overexpressing HSV-1 TK, 10 µM HBPG produced a 67% inhibition of the TK activity present in cell extracts from these cells (data not shown). In these cells, the inhibitor did not induce apoptosis in the presence of IL-3 (Fig. 5B). However, in IL-3-deprived TK-transfected cells, HBPG significantly reduced cell viability (Fig. 5B) and induced a sub-G1 population of apoptotic cells (Fig. 5D) to values similar to those of control cells (Fig. 5, A and D). The inhibition of viral TK by HBPG also increased the sensitivity of TK2 cells to FdUrd and MTX as determined by measuring cell viability (Fig. 5C) or by the generation of sub-G1 cells in cell cycle analysis experiments (Fig. 5D). In summary, these results indicated that the protection from apoptosis in cells overexpressing HSV-1 TK was the direct outcome of the presence of the viral TK activity and not a consequence of the introduction of viral DNA.


Fig. 5. Effect of HBPG on the suppression of apoptosis by HSV-1 TK overexpression. The HSV-1 TK inhibitor HBPG was used at 10 µM final concentration. A and B, the effect of HBPG treatment on the suppression of cell death by HSV-1 TK overexpression after IL-3 removal. In C, results are shown for cell death induced after 15 h of treatment with 10 µM MTX or 10 µM FdUrd in the presence or absence of 10 µM HBPG. Data shown are the average ± S.D. of at least two independent experiments. D, analysis by flow cytometry of apoptosis induced under the experimental conditions presented in previous panels of this figure after 15 h of either IL-3 removal or MTX treatment.
[View Larger Version of this Image (33K GIF file)]


Whereas many intracellular signals are known to decline after removal of IL-3 from dependent cells (31-33), only overexpression of oncogenes such as myc (34) or bcl-2 (21), activators of the ras pathway (35, 36), or activated abl kinase (37) has previously been shown to modulate apoptosis. Our data demonstrate that a single enzyme involved in nucleotide metabolism can exert a similar effect, which suggests that regulation of the dNTP supply may be a control point in apoptosis.

Although mammalian TK expression is cell cycle-regulated, with peak gene expression occurring immediately before entry into S-phase (38), we have demonstrated that IL-3 also regulates TK activity posttranslationally (11). Serum has also been shown to regulate the phosphorylation state and activity of TK in HL-60 cells (24). The vector used in our transfection experiments constitutively expresses HSV TK throughout the cell cycle, and the viral TK does not seem to be down-regulated after withdrawal of IL-3, resulting in increased TK activity even in the absence of IL-3.

Under normal culture conditions, the viability and growth of cells do not seem to require the uptake of exogenous deoxynucleosides unless the endogenous synthesis of dNTP has been inhibited by treatment with drugs (17, 18). This is because most culture media contain high levels of folic acid, which allows the continued synthesis of tetrahydrofolate derivatives required for the synthesis of nucleotides and particularly of thymidylate. However, in culture media containing concentrations of folic acid comparable to the serum levels, the growth of cells is dependent on the supply of exogenous thymidine, and therefore, under these conditions, TK activity should play an important role in the pathway leading to dTTP formation for DNA synthesis and repair (39). Therefore, in cells such as hemopoietic BAF3 cells that are strictly dependent on growth factors for cell viability and proliferation, regulation of TK activity by IL-3 (11) could be an important event in the maintenance of balanced dNTP pools when the extracellular concentration of folic acid is comparable with that of serum.

Due to the complexity of dNTP metabolism and the multiple allosteric mechanisms involved in this metabolism, at present it is difficult to identify the critical variable that induces apoptosis during dNTP pool imbalances. The fact that inhibition of one specific pathway such as that leading to de novo dTTP synthesis might influence the formation of other dNTPs (27) makes it difficult to propose a more specific model. The mechanism by which viral TK overexpression might protect cells from IL-3 removal or dNTP synthesis inhibitors is probably related to the increased capacity of the cell to maintain dNTP pools for DNA repair and synthesis (40). dNTP pool balance has been shown to be essential for fidelity in DNA synthesis in dividing cells (4). In BAF3 cells, IL-3 withdrawal does not result in cell cycle arrest (21), thus DNA synthesis is probably taking place in cells with imbalanced dNTP pools. In other cells, promotion of entry into S-phase by disregulated myc (41) or E2F (42) expression in the absence of growth factors also induces apoptosis. It has been previously shown that nucleotide misincorporation during DNA replication and repair under limiting metabolic conditions (43) may serve as a signal to initiate a death program (8) to avoid the appearance of genetic variants with chromosomal abnormalities. Although the dNTP pool imbalances observed in BAF3 cells may not be sufficiently large to induce an important increase in replication error rates, it is possible to speculate that small changes in DNA replication accuracy or misincorporation of uracil residues into DNA might activate genes that are important for the execution of apoptosis (8) or induce the accumulation of proteins such as p53 that trigger the apoptotic program (44).

Cells lacking TK activity have been shown to have a lower rate of DNA synthesis, a longer generation time (45), and an increased sensitivity to DNA alkylating agents (46) that is probably related to their inability to maintain dTTP pools. These agents are also potent inducers of apoptosis (47). Our results raise the hypothesis that regulation of TK activity by growth factors, and therefore the cellular dNTP levels, could be a checkpoint to signal proliferating cells whether to continue the progression through the cell cycle or to enter a program of cell death by apoptosis. Deregulated expression of cellular TK activity has been reported to be correlated with tumorigenicity (12, 13) and cell resistance to radiation (15). On the other hand, viral TK could be an apoptosis-inhibiting factor during productive or latent infection of cells with herpes simplex virus, acting perhaps in a concerted manner with the viral proteins gamma 34.5 and ICP4, recently described as inhibitors of apoptosis (48, 49).


FOOTNOTES

*   Supported by Grant SAF94-0768 from Comisión Interministerial de Ciencia y Tecnología, Spain, the Cancer Research Campaign, United Kingdom, and the European Community Concerted Action (BMH1-CT93-1530).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
   To whom correspondence should be addressed: Instituto de Parasitología y Biomedicina, Consejo Superior de Investigaciones Científicas c/Ventanilla 11, 18001 Granada, Spain. Tel.: 34-58-20-38-02; Fax: 34-58-20-33-23.
1   The abbreviations used are: dNTP, deoxyribonucleoside triphosphate; IL-3, interleukin-3; FdUrd, 5-fluoro-2'-deoxyuridine; HBPG, 9-(4-hydroxybutyl)-N2-phenylguanine; HSV, herpes simplex virus; TK, thymidine kinase; HU, hydroxyurea; MTX, methotrexate; PBS, phosphate-buffered saline.

REFERENCES

  1. Liebermann, D. A., Hoffman, B., and Steinman, R. A. (1995) Oncogene 11, 199-210 [Medline] [Order article via Infotrieve]
  2. Smets, L. A. (1994) Anticancer Drugs 5, 3-9 [Medline] [Order article via Infotrieve]
  3. Miyashita, T., and Reed, J. C. (1992) Cancer Res. 52, 5407-5411 [Abstract]
  4. Reichard, P. (1988) Annu. Rev. Biochem. 57, 349-374 [CrossRef][Medline] [Order article via Infotrieve]
  5. Mathews, C. K., and Ji, J. (1992) BioEssays 14, 295-301 [Medline] [Order article via Infotrieve]
  6. Bradley, M. O., and Sharkey, N. A. (1978) Nature 274, 707-709
  7. Brox, L., Ng, A., Pollock, E., and Belch, A. (1984) Cancer Res. 44, 934-940 [Abstract]
  8. Yoshioka, A., Tanaka, S., Hiraoka, O., Koyama, Y., Hirota, Y., Ayusawa, D., Seno, T., Garrett, C., and Wataya, Y. (1987) J. Biol. Chem. 262, 8235-8241 [Abstract/Free Full Text]
  9. Martin, D. W., and Gelfand, E. W. (1981) Annu. Rev. Biochem. 50, 845-877 [CrossRef][Medline] [Order article via Infotrieve]
  10. Oliver, F. J., Marvel, J., Collins, M. K. L., and López-Rivas, A. (1993) Biochem. Biophys. Res. Commun. 194, 126-132 [CrossRef][Medline] [Order article via Infotrieve]
  11. Oliver, F. J., Collins, M. K. L., and López-Rivas, A. (1996) Biochem. J. 316, 421-425 [Medline] [Order article via Infotrieve]
  12. Yusa, T., Yamaguchi, Y., Ohwada, H., Hayashi, Y., Morita, T., Asanagi, M., Moriyama, I., and Fujimura, S. (1988) Cancer Res. 48, 5001-5006 [Abstract]
  13. Hallek, M., Wanders, L., Strohmeyer, S., and Emmerich, B. (1992) Ann. Hematol. 65, 1-5 [Medline] [Order article via Infotrieve]
  14. Rothschild, H., and Black, P. H. (1970) Proc. Natl. Acad. Sci. U. S. A. 67, 1042-1049 [Abstract]
  15. Al-Nabulsi, I., Takayima, Y., Volishin, Y., Dritschilo, A., Martuza, R. L., and Jorgensen, T. (1994) Cancer Res. 54, 5614-5617 [Abstract]
  16. Koury, M. J., and Horne, D. W. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4067-4071 [Abstract]
  17. Curtin, N. J., Harris, A. L., and Aherne, G. W. (1991) Cancer Res. 51, 2346-2352 [Abstract]
  18. Van Mouwerick, T. J., Pangallo, C. A., Willson, J. K., and Fisher, P. H. (1987) Biochem. Pharmacol. 36, 809-814 [Medline] [Order article via Infotrieve]
  19. Palacios, R., and Steimetz, M. (1985) Cell 41, 727-734 [Medline] [Order article via Infotrieve]
  20. Morgenstern, J. P., and Land, H. (1990) Nucleic Acids Res. 18, 3587-3596 [Abstract]
  21. Collins, M. K. L., Marvel, J., Malde, P., and López-Rivas, A. (1993) J. Exp. Med. 176, 1043-1051 [Abstract]
  22. Lindberg, U., and Skoog, L. (1979) Anal. Biochem. 34, 152-160
  23. North, T. W., Bestwick, R. K., and Mathews, C. K. (1980) J. Biol. Chem. 255, 6640-6645 [Abstract/Free Full Text]
  24. Chang, Z.-F., and Huang, D.-Y. (1993) J. Biol. Chem. 268, 1266-1271 [Abstract/Free Full Text]
  25. Lagergren, J., and Reichard, P. (1987) Biochem. Pharmacol. 36, 2985-2991 [CrossRef][Medline] [Order article via Infotrieve]
  26. Honess, R. W., and Watson, D. H. (1974) J. Gen. Virol. 22, 171-185 [Medline] [Order article via Infotrieve]
  27. Thelander, L., and Reichard, P. (1979) Annu. Rev. Biochem. 48, 133-158 [CrossRef][Medline] [Order article via Infotrieve]
  28. Lewis, J. A., and Esteban, M. (1984) Virology 133, 464-469 [Medline] [Order article via Infotrieve]
  29. Lewis, J. A., Mengheri, E., and Esteban, M. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 26-30 [Abstract]
  30. Xu, H., Maga, G., Focher, F., Smith, E. R., Spadari, S., Gambino, J., and Wright, G. E. (1984) J. Med. Chem. 38, 49-57
  31. Whetton, D., and Dexter, T. M. (1983) Nature 30, 639-642
  32. Linnekin, D., and Farrar, W. L. (1990) Biochem. J. 271, 317-324 [Medline] [Order article via Infotrieve]
  33. Whetton, A. D., Vallance, S. J., Monk, P. N., Cragoe, E. J., Dexter, T. M., and Heyworth, C. M. (1988) Biochem. J. 256, 585-592 [Medline] [Order article via Infotrieve]
  34. Askew, D. S., Ashmun, R., Simmons, B. C., and Cleveland, J. L. (1991) Oncogene 6, 1915-1922 [Medline] [Order article via Infotrieve]
  35. Sato, N., Sakamaki, K., Terada, N., Arai, K., and Mikayima, A. (1993) EMBO J. 12, 4181-4189 [Abstract]
  36. Perkins, G. R., Marshall, C. J., and Collins, M. K. L. (1996) Blood 87, 3669-3675 [Abstract/Free Full Text]
  37. McGahon, A., Bissonnette, R., Schmitt, M., Cotter, K. M., Green, D. R., and Cotter, T. G. (1994) Blood 83, 1179-1187 [Abstract/Free Full Text]
  38. Adler, R., and McAuslan, B. R. (1974) Cell 2, 113-117 [Medline] [Order article via Infotrieve] , 1974
  39. Taylor-Papadimitriou, J., and Rozengurt, E. (1979) Exp. Cell Res. 119, 393-396 [Medline] [Order article via Infotrieve]
  40. Kit, S., Leung, W.-C., Trkula, D., and Jorgensen, G. (1974) Int. J. Cancer 13, 203-218 [Medline] [Order article via Infotrieve]
  41. Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., and Hancock, D. C. (1992) Cell 69, 119-128 [Medline] [Order article via Infotrieve]
  42. Shan, B., and Lee, W. H. (1994) Mol. Cell. Biol. 14, 8166-8173 [Abstract]
  43. Bebenek, K., and Kunkel, T. A. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 4946-4950 [Abstract]
  44. Almasan, A., Yin, Y., Kelly, R. E., Lee, E. Y.-H. P., Bradley, A., Li, W., Bertino, J. R., and Wahl, G. M. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 5436-5440 [Abstract]
  45. Höglund, L., Pontis, E., and Reichard, P. (1987) Cancer Res. 48, 3681-3690 [Abstract] , 1987
  46. Wakazono, Y., Kubota, M., Furusho, K., Liu, L., and Gerson, S. L. (1996) Mutat. Res. 362, 119-125 [Medline] [Order article via Infotrieve]
  47. Schreiber, V., Hunting, D., Trucco, C., Gowans, B., Grunwald, D., de Murcia, G., and Ménissier de Murcia, J. (1995) Proc. Natl. Acad. Sci. U. S. A. 11, 4753-4757
  48. Leopardi, R., and Roizman, B. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 9583-9587 [Abstract/Free Full Text]
  49. Chou, J., Chen, J.-J., Gross, M., and Roizman, B. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10516-10520 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.